English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Objective   In the recent time, endoradionuclide therapy for metastatic castration-resistant prostate carcinoma employing  177 Lu-PSMA-617 has yielded encouraging results and several clinical trials with the agent are currently ongoing. Routine preparation of  177 Lu-PSMA-617 patient doses can be made simpler and convenient, if the ingredients essential for radiolabeling are made available in a ready-to-use lyophilized form.Methods   PSMA-617 freeze-dried kit was formulated and used for the preparation of  177 Lu-PSMA-617 clinical dose with high radiochemical purity using low/medium specific activity  177 Lu. Detailed radiochemical studies were performed to determine the maximum activity and volume of  177 LuCl 3 , which can be added in the kit for the formulation of  177 Lu-PSMA-617. Studies were also performed to determine the shelf life of the kit to ensure its long-term usage. Studies were performed in buffer as well as human serum medium to determine the stability of the  177 Lu-PSMA-617 complex after storing in respective media up to 7 days postpreparation. About ten patient doses of  177 Lu-PSMA-617 were administered, and posttherapy scans were acquired.Results   The formulated freeze-dried kit of PSMA-617 could be radiolabeled with an average percentage radiochemical purity > 98.53 ± 0.38. The freeze-dried kit was found suitable for tolerating up to 0.5 mL of  177 LuCl 3  (in 0.01 N HCl) and specific activity of 555 MBq/ μ g (15 mCi/ μ g) for the preparation of the patient dose of  177 Lu-PSMA-617. The  177 Lu-PSMA-617 complex prepared using the freeze-dried kit of PSMA-617 was observed to maintain % radiochemical purity (RCP) of 96.74 ± 0.87 and 94.81 ± 2.66, respectively, even after storing up to 7 days in buffer and human serum, respectively.  177 Lu-PSMA-617 prepared using the in-house formulated freeze-dried kit of PSMA-617 exhibited accumulation in metastatic lesions picked up in a pretherapy PET scan. Reduction in number as well as size of lesions was observed in posttherapy scans acquired after two months of administering the first therapeutic dose of  177 Lu-PSMA-617.Conclusions   The freeze-dried kit of PSMA-617 could be used for the preparation of  177 Lu-PSMA-617 with high radiochemical purity (>98%) in a reproducible manner.  177 Lu-PSMA-617 prepared using the developed kit was successfully evaluated in patients suffering from metastatic prostate cancer.

biomed research international

Preparation of 177Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House